Evaluation of the effects of sulfamethoxazole on Toxoplasma gondii loads and stage conversion in IFN-γ knockout mice using QC-PCR

被引:14
作者
Belal, US
Norose, K
Aosai, F
Mun, HS
Ahmed, AK
Chen, M
Mohamed, RM
Piao, LX
Iwakura, Y
Yano, A
机构
[1] Chiba Univ, Grad Sch Med, Dept Infect & Host Def, Chuo Ku, Chiba 2608670, Japan
[2] Univ Tokyo, Inst Med Sci, Ctr Med Expt, Minato Ku, Tokyo 1088639, Japan
关键词
Toxoplasma gondii; immunocompromised hosts; chemotherapy; sulfamethoxazole; stage conversion; interferon gamma;
D O I
10.1111/j.1348-0421.2004.tb03504.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Toxoplasma gondii abundance with or without sulfamethoxazole treatment was evaluated by quantitative competitive polymerase chain reaction (QC-PCR) assay in various organs of IFN-gamma knockout BALB/c (B/c) mice after peroral infection with the cyst-forming Fukaya strain. T gondii infection was observed in the brain, skin, tongue, heart, and skeletal muscle of the mice treated with sulfamethoxazole, although the parasite was not observed during the treatment in the mesenteric lymph node, spleen, small intestine or kidney. After discontinuing the therapy, T gondii reappeared within five days in all organs. Reverse transcriptase (RT)-PCR showed that sulfamethoxazole treatment accelerated the stage conversion of T gondii from tachyzoites into bradyzoites in the brain, lung, and heart. In contrast, after discontinuing sulfamethoxazole treatment, T gondii underwent stage conversion from bradyzoites into tachyzoites in these organs. These results indicate that we successfully established an animal model for evaluating chemotherapy regimens in immunocompromised hosts infected with T. gondii.
引用
收藏
页码:185 / 193
页数:9
相关论文
共 39 条
  • [1] BERGIN C, 1992, EUR RESPIR J, V5, P1018
  • [2] BERTOLI F, 1995, ARCH PATHOL LAB MED, V119, P214
  • [3] CLONING AND CHARACTERIZATION OF A BRADYZOITE-SPECIFICALLY EXPRESSED GENE (HSP30/BAG1) OF TOXOPLASMA-GONDII, RELATED TO GENES ENCODING SMALL HEAT-SHOCK PROTEINS OF PLANTS
    BOHNE, W
    GROSS, U
    FERGUSON, DJP
    HEESEMANN, J
    [J]. MOLECULAR MICROBIOLOGY, 1995, 16 (06) : 1221 - 1230
  • [4] BURG JL, 1988, J IMMUNOL, V141, P3584
  • [5] RELAPSE OF TOXOPLASMA-ENCEPHALITIS AND SUSCEPTIBILITY TO PYRIMETHAMINE - LACK OF EVIDENCE OF TREATMENT-INDUCED RESISTANCE
    CARAMELLO, P
    BRANCALE, T
    FORNO, B
    LUCCHINI, A
    POLLONO, AM
    ULLIO, A
    GIOANNINI, P
    VIANO, I
    TONSO, E
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) : 2371 - 2372
  • [6] Congenital toxoplasma chorioretinitis transmitted by preconceptionally immune women
    Dollfus, H
    Dureau, P
    Hennequin, C
    Uteza, Y
    Bron, A
    Dufier, JL
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (12) : 1444 - 1445
  • [7] Advances in the life cycle of Toxoplasma gondii
    Dubey, JP
    [J]. INTERNATIONAL JOURNAL FOR PARASITOLOGY, 1998, 28 (07) : 1019 - 1024
  • [8] Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models
    Dumas, JL
    Pizzolato, G
    Pechère, JC
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 13 (01) : 35 - 39
  • [9] Toxoplasmosis in heart transplant recipients
    Gallino, A
    Maggiorini, M
    Kiowski, W
    Martin, X
    Wunderli, W
    Schneider, J
    Turina, M
    Follath, F
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (05) : 389 - 393
  • [10] GAZZINELLI R, 1992, J IMMUNOL, V149, P175